The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
Open accessAbstract
Parkinson's disease psychosis (PDP) is a condition that may develop in up to 60 % of Parkinson's patients, and is a major reason for nursing home placement for those affected. There are no FDA approved drugs for PDP but low doses of atypical anti-psychotic drugs (APDs) are commonly prescribed off-label. Only low-dose clozapine has shown efficacy in randomized controlled trials, but all APDs have black box warnings related to the increased mortality and morbidity when used in elderly demented patients. Using molecular pharmacological profiling of a large collection of marketed drugs, we discovered that potent inverse agonist activity against 5-HT2A serotonin receptors was a common feature of atypical APDs, especially the atypical APDs used to treat PDP. Since low-dose clozapine therapy selectively blocks this receptor, it was hypothesized that a highly selective 5-HT2A receptor inverse agonist might provide good symptom control in patients suffering from PDP, with a greatly improved safety and tolerability profile. A high throughput screening and subsequent chemical lead optimization campaign to develop potent, selective 5-HT2A receptor inverse agonists was launched, eventually resulting in the discovery of pimavanserin. Pimavanserin displays nanomolar potency as a 5-HT2A receptor inverse agonist, selectivity for 5-HT2A over 5-HT2C receptors, and no meaningful activity at any other G-protein coupled receptor. It demonstrated robust activity in preclinical models of schizophrenia and PDP, and did not worsen motoric symptoms, in contrast to the APDs tested. In a Phase III clinical trial, pimavanserin showed highly significant benefits in the primary endpoint, the scale for assessment of positive symptoms-PD, a scale adapted for use in PDP. In addition, improvements in all other efficacy endpoints, including physician's clinical global impression, caregiver burden, night-time sleep quality and daytime wakefulness, were seen. Pimavanserin demonstrated good safety and tolerability and did not worsen motoric symptoms as assessed by the unified Parkinson's disease rating scale parts II and III. An open-label extension study has further demonstrated that pimavanserin is safe and well-tolerated with long-term use. Pimavanserin may therefore offer a viable treatment option for patients suffering from PDP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., & Ballard, C. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
Self-citationLow-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
(1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401003 · Cited by 615
Risk factors for nursing home placement in advanced Parkinson's disease
Goetz, C. G., & Stebbins, G. T. (1993) · Neurology · doi:10.1212/wnl.43.11.2227 · Cited by 455
A 12-Year Population-Based Study of Psychosis in Parkinson Disease
Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., Goetz, C. G., Stebbins, G. T., Aarsland, D., & Alves, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.166 · Cited by 394
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1444 · Cited by 339
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
Self-citationSerotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.35 · Cited by 266
Clozapine in drug-induced psychosis in Parkinson's disease
(1999) · The Lancet · doi:10.1016/s0140-6736(99)00860-0 · Cited by 230
Vanover, K. E., Weiner, D. M., Makhay, M., Veinbergs, I., Gardell, L. R., Lameh, J., Del Tredici, A. L., Piu, F., Schiffer, H. H., Ott, T. R., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097006 · Cited by 204
Self-citation5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics
Weiner, D. M., Burstein, E. S., Nash, N., Croston, G. E., Currier, E. A., Vanover, K. E., Harvey, S. C., Donohue, E., Hansen, H. C., Andersson, C. M., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29327-7 · Cited by 203
Self-citationVarty, G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00072-4 · Cited by 202
Milestones in Parkinson's disease therapeutics
Rascol, O., Lozano, A., Stern, M., & Poewe, W. (2011) · Movement Disorders · doi:10.1002/mds.23714 · Cited by 198
Shapiro, D. A., Kristiansen, K., Weiner, D. M., Kroeze, W. K., & Roth, B. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111675200 · Cited by 172
Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain
Zhou, F., Bledsoe, S. B., & Murphy, J. M. (1991) · Brain Research · doi:10.1016/0006-8993(91)90553-8 · Cited by 138
Burstein, E. S., Spalding, T. A., & Brann, M. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.38.24322 · Cited by 119
Self-citationPatterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Weintraub, D. A., Chen, P., Ignacio, R. V., Mamikonyan, E., & Kales, H. C. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.139 · Cited by 118
Pharmacology of Muscarinic Receptor Subtypes Constitutively Activated by G Proteins
Burstein, E. S., Spalding, T. A., & Brann, M. R. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.2.312 · Cited by 113
Self-citationMeltzer, H. Y., Elkis, H., Vanover, K. E., Weiner, D. M., van Kammen, D. P., Peters, P., & Hacksell, U. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.029 · Cited by 104
Self-citationHigh 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET
Nordström, A., Farde, L., & Halldin, C. (1993) · Psychopharmacology · doi:10.1007/bf02251294 · Cited by 102
Parkinson Disease Psychosis: Update
Friedman, J. H. (2013) · Behavioural Neurology · doi:10.1155/2013/645429 · Cited by 98
Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial)
Ballard, C. G., Brown, R. G., Fossey, J., Douglas, S., Bradley, P., Hancock, J., James, I. A., Juszczak, E., Bentham, P., Burns, A. S., et al. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181b0f8c0 · Cited by 93
Nonmotor Manifestations in Parkinson Disease
Bernal-Pacheco, Ó., Limotai, N., Go, C. L., & Fernandez, H. H. (2012) · The Neurologist · doi:10.1097/nrl.0b013e31823d7abb · Cited by 92
Boulet, S., Mounayar, S., Poupard, A., Bertrand, A., Jan, C., Pessiglione, M., Hirsch, É. C., Feuerstein, C., François, C., Féger, J., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3465-08.2008 · Cited by 89
Rozas, G., Liste, I., Guerra, M. J., & Labandeira-García, J. L. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00198-0 · Cited by 88
Voss, T., Bahr, D., Cummings, J. L., Mills, R., Ravina, B. M., & Williams, H. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.10.022 · Cited by 85
Self-citationStructure-Function of Muscarinic Receptor Coupling to G Proteins
Burstein, E. S., Spalding, T. A., Hill‐Eubanks, D. C., & Brann, M. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.3141 · Cited by 79
Self-citationMK-801-induced hyperlocomotion: Differential effects of M100907, SDZ PSD 958 and raclopride
Martin, P., Waters, N., Waters, N., Carlsson, A., & Carlsson, M. L. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01188-6 · Cited by 77
Quetiapine in the treatment of psychosis in Parkinson’s disease
Shotbolt, P., Samuel, M., & David, A. S. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610389656 · Cited by 75
Bruno, J. P., Jackson, D., Zigmond, M. J., & Stricker, E. M. (1987) · Behavioral Neuroscience · doi:10.1037/0735-7044.101.6.806 · Cited by 73
Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis.
Spalding, T. A., Burstein, E. S., Bräuner‐Osborne, H., et al. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12181-2 · Cited by 65
Self-citationAn update expert opinion on management and research strategies in Parkinson's disease psychosis
Goldman, J. G., Vaughan, C. L., & Goetz, C. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.587122 · Cited by 56
Ancoli‐Israel, S., Vanover, K. E., Weiner, D. M., Davis, R. E., & van Kammen, D. P. (2011) · Sleep Medicine · doi:10.1016/j.sleep.2010.10.004 · Cited by 54
Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model
Zhang, X., Andrén, P. E., & Svenningsson, P. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.033 · Cited by 53
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain
Nordström, A., Månsson, M., Jovanovic, H., Karlsson, P., Halldin, C., Farde, L., Vanover, K. E., Hacksell, U., Brann, M. R., Davis, R. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007869 · Cited by 52
Self-citationCurrent Use of Clozapine in Parkinson Disease and Related Disorders
Thomas, A. A., & Friedman, J. H. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181c47168 · Cited by 51
Balcioglu, A., Zhang, K., & Tarazi, F. I. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00219-7 · Cited by 46
Vanover, K. E., Robbins‐Weilert, D., Wilbraham, D. G., Mant, T., van Kammen, D. P., Davis, R. E., & Weiner, D. M. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007299431 · Cited by 40
Constitutive Activity of Muscarinic Acetylcholine Receptors
Spalding, T. A., & Burstein, E. S. (2006) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890600567349 · Cited by 38
Self-citationVanover, K. E., Harvey, S. C., Son, T., Bradley, S. R., Kold, H., Makhay, M. M., Veinbergs, I., Spalding, T. A., Weiner, D. M., Andersson, C., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.066688 · Cited by 28
Self-citationHubbard, D. T., Hacksell, U., & McFarland, K. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283656db6 · Cited by 18
Self-citation
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Psychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities
Ismail, Z., Creese, B., Aarsland, D., Kales, H. C., Lyketsos, C. G., Sweet, R. A., & Ballard, C. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00597-3 · Cited by 189
Trial of pimavanserin in dementia-related psychosis
Tariot, P. N., Cummings, J. L., Soto-Martin, M. E., Ballard, C., Erten-Lyons, D., Sultzer, D. L., Devanand, D. P., Weintraub, D., McEvoy, B., Youakim, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034634 · Cited by 145
Ballard, C., Youakim, J. M., Coate, B., & Stankovic, S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.30 · Cited by 40
Cao, Y., Yu, F., Lyu, Y., & Lu, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1034243 · Cited by 26
Metadata
- Authors
- Hacksell, U., Burstein, E. S., McFarland, K., Mills, R. G., & Williams, H.
- Venue
- Neurochemical Research
- Published
- 2014-03-30
- Volume
- 39
- Issue
- 10
- Pages
- 2008-2017
- ISSN
- 0364-3190 (ISSN-L)
- 1573-6903
- OpenAlex
- W1968565337
- Cited by
- 297
- References
- 40
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.